ANI Pharmaceuticals, Inc. (ANIP)

NASDAQ: ANIP · Real-Time Price · USD
61.44
+3.06 (5.24%)
Nov 8, 2024, 4:00 PM EST - Market closed
5.24%
Market Cap 1.20B
Revenue (ttm) 555.46M
Net Income (ttm) -10.40M
Shares Out 19.52M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE 11.35
Dividend n/a
Ex-Dividend Date n/a
Volume 332,005
Open 61.58
Previous Close 58.38
Day's Range 57.80 - 62.27
52-Week Range 48.20 - 70.81
Beta 0.71
Analysts Buy
Price Target 76.80 (+25.0%)
Earnings Date Nov 8, 2024

About ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmac... [Read more]

Sector Healthcare
Founded 2001
Employees 642
Stock Exchange NASDAQ
Ticker Symbol ANIP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ANIP stock is "Buy." The 12-month stock price forecast is $76.8, which is an increase of 25.00% from the latest price.

Price Target
$76.8
(25.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz ...

1 day ago - Seeking Alpha

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

BAUDETTE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended Se...

2 days ago - GlobeNewsWire

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Ste...

5 days ago - GlobeNewsWire

ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET

PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial resu...

10 days ago - GlobeNewsWire

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administratio...

16 days ago - GlobeNewsWire

ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024

Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care

17 days ago - GlobeNewsWire

ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential

Piper Sandler has initiated coverage on ANI Pharmaceuticals ANIP, an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines.

4 weeks ago - Benzinga

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 millio...

4 weeks ago - Seeking Alpha

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administrati...

6 weeks ago - GlobeNewsWire

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera ...

7 weeks ago - GlobeNewsWire

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previousl...

7 weeks ago - GlobeNewsWire

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution

PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobr...

2 months ago - GlobeNewsWire

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

PRINCETON, N.J. & ATLANTA--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they ha...

2 months ago - Business Wire

ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announc...

2 months ago - GlobeNewsWire

Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement

ATLANTA--(BUSINESS WIRE)--Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retin...

2 months ago - Business Wire

ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alimera Sciences...

2 months ago - Business Wire

ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers' Option to Purchase Additional Notes

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount ...

3 months ago - GlobeNewsWire

ANI Pharmaceuticals, Inc. (ANIP) Q2 2024 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - ...

3 months ago - Seeking Alpha

ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the pricing of its offering of $275,000,000 aggregate principal amount ...

3 months ago - GlobeNewsWire

ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced its intention to offer, subject to market and other conditions, $250,00...

3 months ago - GlobeNewsWire

ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance

BAUDETTE, Minn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended Ju...

3 months ago - GlobeNewsWire

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochl...

3 months ago - Seeking Alpha

ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder

PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administratio...

4 months ago - GlobeNewsWire

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for t...

4 months ago - GlobeNewsWire

ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner

Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impac...

4 months ago - GlobeNewsWire